Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer

The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosyl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Publicado:	2018
Materias:	asparagine linked oligosaccharide epidermal growth factor glycan glycogen synthase kinase transcription factor 4 polysaccharide programmed death 1 ligand 1 cancer immunotherapy cytotoxicity ectopic expression endocytosis glycosylation human immunosuppressive treatment lysosome nonhuman priority journal protein protein interaction Short Survey treatment response triple negative breast cancer tumor microenvironment tumor rejection upregulation immunotherapy B7-H1 Antigen Humans Immunotherapy Polysaccharides Triple Negative Breast Neoplasms
Acceso en línea:	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_15356108_v33_n2_p155_Salatino http://hdl.handle.net/20.500.12110/paper_15356108_v33_n2_p155_Salatino
Aporte de:	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

id	paper:paper_15356108_v33_n2_p155_Salatino
record_format	dspace
spelling	paper:paper_15356108_v33_n2_p155_Salatino2023-06-08T16:20:06Z Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer asparagine linked oligosaccharide epidermal growth factor glycan glycogen synthase kinase transcription factor 4 polysaccharide programmed death 1 ligand 1 cancer immunotherapy cytotoxicity ectopic expression endocytosis glycosylation human immunosuppressive treatment lysosome nonhuman priority journal protein protein interaction Short Survey treatment response triple negative breast cancer tumor microenvironment tumor rejection upregulation immunotherapy B7-H1 Antigen Humans Immunotherapy Polysaccharides Triple Negative Breast Neoplasms The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. © 2018 Elsevier Inc. 2018 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_15356108_v33_n2_p155_Salatino http://hdl.handle.net/20.500.12110/paper_15356108_v33_n2_p155_Salatino
institution	Universidad de Buenos Aires
institution_str	I-28
repository_str	R-134
collection	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic	asparagine linked oligosaccharide epidermal growth factor glycan glycogen synthase kinase transcription factor 4 polysaccharide programmed death 1 ligand 1 cancer immunotherapy cytotoxicity ectopic expression endocytosis glycosylation human immunosuppressive treatment lysosome nonhuman priority journal protein protein interaction Short Survey treatment response triple negative breast cancer tumor microenvironment tumor rejection upregulation immunotherapy B7-H1 Antigen Humans Immunotherapy Polysaccharides Triple Negative Breast Neoplasms
spellingShingle	asparagine linked oligosaccharide epidermal growth factor glycan glycogen synthase kinase transcription factor 4 polysaccharide programmed death 1 ligand 1 cancer immunotherapy cytotoxicity ectopic expression endocytosis glycosylation human immunosuppressive treatment lysosome nonhuman priority journal protein protein interaction Short Survey treatment response triple negative breast cancer tumor microenvironment tumor rejection upregulation immunotherapy B7-H1 Antigen Humans Immunotherapy Polysaccharides Triple Negative Breast Neoplasms Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
topic_facet	asparagine linked oligosaccharide epidermal growth factor glycan glycogen synthase kinase transcription factor 4 polysaccharide programmed death 1 ligand 1 cancer immunotherapy cytotoxicity ectopic expression endocytosis glycosylation human immunosuppressive treatment lysosome nonhuman priority journal protein protein interaction Short Survey treatment response triple negative breast cancer tumor microenvironment tumor rejection upregulation immunotherapy B7-H1 Antigen Humans Immunotherapy Polysaccharides Triple Negative Breast Neoplasms
description	The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. © 2018 Elsevier Inc.
title	Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
title_short	Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
title_full	Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
title_fullStr	Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
title_full_unstemmed	Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
title_sort	glycans pave the way for immunotherapy in triple-negative breast cancer
publishDate	2018
url	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_15356108_v33_n2_p155_Salatino http://hdl.handle.net/20.500.12110/paper_15356108_v33_n2_p155_Salatino
_version_	1768544656434397184

Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer

Ejemplares similares